NIH director Francis Collins at a Senate Appropriations subcommittee hearing for Operation Warp Speed (Graeme Jennings/Pool via AP Images)

Covid-19 roundup: As­traZeneca signs 400M vac­cine sup­ply deal with EU; Sinopharm re­ports pos­i­tive Phase I/II da­ta for vac­cine can­di­date

Amid talks with mul­ti­ple play­ers, the Eu­ro­pean Com­mis­sion has reached its first vac­cine sup­ply deal with As­traZeneca, se­cur­ing 400 mil­lion dos­es of the Ox­ford can­di­date for all of its mem­ber coun­tries.

The phar­ma gi­ant said in a press re­lease that the deal builds on the ex­ist­ing agree­ment with Ger­many, France, Italy and the Nether­lands, an­nounced in June. It was un­clear, how­ev­er, whether that means sim­ply ex­tend­ing the same 400 mil­lion dos­es to all EU coun­tries or dou­bling the reser­va­tion to 800 mil­lion dos­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.